Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), headquartered in Marlborough, Massachusetts, is a clinical-stage biotechnology company focused on developing innovative immuno-oncology therapeutics. The company's proprietary INTASYL™ siRNA gene silencing technology is at the forefront of its efforts to enhance the effectiveness of immune cells in targeting and destroying tumor cells.
Phio's core product pipeline includes:
- PH-762: Targets the checkpoint protein PD-1 on immune cells, enhancing their ability to attack tumors. Currently in Phase 1b clinical trials, PH-762 is being tested for its efficacy in treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
- PH-804: Focuses on the suppressive immune receptor TIGIT, present on T cells and natural killer cells, to bolster immune responses against cancer.
- PH-790: Aims to silence the PD-L1 protein, which normally prevents immune cells from attacking non-harmful cells, thereby boosting the body's natural defenses against cancer.
Phio Pharmaceuticals collaborates with leading institutions such as Gustave Roussy, Medigene AG, and Helmholtz Zentrum München to advance their research and development efforts. The company's financial health, as of the latest reports, shows a cash position of $6.5 million, with a significant reduction in research and development expenses aimed at transitioning from discovery to product development.
Phio's latest updates include the presentation of new data on PH-762 at various scientific conferences and the initiation of new partnerships. These efforts underscore Phio's commitment to delivering cutting-edge cancer treatments and improving patient outcomes.
For more details, visit the company's website at www.phiopharma.com.
Rhea-AI Summary
Phio Pharmaceuticals Corp. announces that its INTASYL platform will be showcased on a national program hosted by Dennis Quaid, airing on PBS and Fox Business Network in April. The program aims to highlight the company's innovative siRNA gene silencing technology designed to enhance immune cells' ability to combat tumor cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
-
Rhea-AI Summary
Phio Pharmaceuticals Corp. reported financial results for 2023 and provided business updates. They made progress with their lead product candidate PH-762, submitted IND to FDA, received clearance for trials in skin cancer, and have two patients completed treatment. They have four sites participating in the trial. They entered a collaboration agreement with AgonOx for a Phase 1 trial. They implemented cost rationalization and filed new patents. Scientific data on INTASYL compounds were presented. Financially, they had $8.5 million cash in 2023, reduced R&D and G&A expenses, and a net loss of $10.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
-
Rhea-AI Summary
Phio Pharmaceuticals Corp. (PHIO) announced the presentation of new data at the Immunotherapy Conference in Munich. The company focuses on INTASYL™ siRNA gene silencing technology to enhance immune cells' ability to kill tumor cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.5%
Tags
Rhea-AI Summary
Phio Pharmaceuticals Corp. announced the addition of three clinical trial sites for its Phase 1b study of PH-762, an INTASYL compound silencing PD-1 to enhance T cells' ability to kill cancer cells. The study aims to evaluate safety, tolerability, tumor response, and dosing for patients with skin cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
-
Rhea-AI Summary
Phio Pharmaceuticals Corp. announced the USPTO granted patents for RXI-185 and RXI-231, targeting age-related skin disorders like photo-aging and hyperpigmentation. The compounds aim to down-regulate MMP1 and TYR proteins, improving skin elasticity, thickening, and reducing pigmentation. The company now holds 81 patents, with a focus on INTASYL siRNA technology for cancer immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
-
Rhea-AI Summary
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced new preclinical data demonstrating the potential of INTASYL self-delivering siRNA targeting Cbl-b to improve natural killer (NK) cell activity for adoptive cell therapy, presenting at the 10th Immunotherapy of Cancer Conference in Germany. The data shows the potential for a more effective cell therapy for hematological malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
Rhea-AI Summary
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announces the exercise of warrants by accredited investors, expected to generate approximately $2.8 million in gross proceeds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-42.14%
Tags
-
Rhea-AI Summary
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) reports Q3 financial results and business update, enrolling first patient in US clinical trial for PH-762, a novel immuno-oncology therapy for skin cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
-
Rhea-AI Summary
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the dosing of the first patient in the Phase 1b clinical trial of PH-762, an INTASYL compound that reduces the expression of PD-1, a protein that inhibits T cells’ ability to kill cancer cells. The trial aims to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762 and assess the tumor response in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.53%
Tags
Rhea-AI Summary
Phio Pharmaceuticals Corp. announced new preclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The data highlights the benefit of combining their INTASYL compound targeting CTLA-4 with systemic anti-PD-1 antibody therapy. The combination significantly enhanced the efficacy of anti-PD-1 therapy, leading to complete regression of around 40% of treated tumors in a mouse model. The INTASYL compound also improved the efficacy of anti-PD-1 therapy on tumors not directly treated with the compound. Additionally, it increased the percentage of reactive CD8+ T cells while decreasing immunosuppressive macrophages in the tumor micro-environment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.57%
Tags
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
The current stock price of Phio Pharmaceuticals (PHIO) is $2.2 as of December 24, 2024.
What is the market cap of Phio Pharmaceuticals (PHIO)?
The market cap of Phio Pharmaceuticals (PHIO) is approximately 2.3M.
What does Phio Pharmaceuticals Corp. do?
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics to enhance the effectiveness of immune cells in killing tumor cells using its proprietary INTASYL™ siRNA gene silencing technology.
What is INTASYL™ technology?
INTASYL™ is Phio Pharmaceuticals' proprietary self-delivering RNAi technology designed to target specific proteins that inhibit the body's immune response against cancer, without the need for specialized formulations or delivery systems.
What are Phio's key products?
Phio's key products include PH-762, targeting PD-1; PH-804, targeting TIGIT; and PH-790, targeting PD-L1, all aimed at boosting the immune system’s ability to combat cancer.
Who are Phio's collaboration partners?
Phio collaborates with notable institutions such as Gustave Roussy, Medigene AG, and Helmholtz Zentrum München.
What recent achievements has Phio Pharmaceuticals announced?
Recent achievements include the presentation of new data on PH-762, progress in clinical trials, and new partnerships aimed at advancing their immuno-oncology programs.
What is the financial condition of Phio Pharmaceuticals?
As of the latest reports, Phio Pharmaceuticals has a cash position of $6.5 million. The company has reduced research and development expenses to focus on transitioning from discovery to product development.
What is PH-762?
PH-762 is an INTASYL compound that targets the PD-1 protein on immune cells, enhancing their ability to attack cancer cells. It is currently in Phase 1b clinical trials.
What cancers is PH-762 being tested for?
PH-762 is being tested for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma in its Phase 1b clinical trials.
What is the significance of INTASYL™ technology?
INTASYL™ technology is significant because it allows for precise targeting of proteins that reduce the body's ability to fight cancer, improving the effectiveness of immune cells without the need for specialized drug delivery systems.
Where can I find more information about Phio Pharmaceuticals?
For more information, you can visit Phio Pharmaceuticals' official website at www.phiopharma.com.
Phio Pharmaceuticals Corp.
Nasdaq:PHIO
PHIO Rankings
PHIO Stock Data
2.32M
1.24M
4.81%
3.02%
5.98%
Biotechnology
Pharmaceutical Preparations
United States of America
MARLBOROUGH